trial

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

NCTId NCT03201757
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 523 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2023-09-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
523 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2017-06-15
Primary completion
2023-09-06
Eligibility
ALL · 16 Years · 70 Years

Interventions & indications

Drugs
ALKS 3831

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Alkermes Medical Director, MDStudy Director

Sites

85 total
Little Rock, United StatesRogers, United StatesAnaheim, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLong Beach, United StatesOakland, United StatesOceanside, United StatesOrange, United StatesPalo Alto, United States

Linked catalysts

1
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatmen — primary completion2023-09-06

Facts & assertions

4 sourced
Enrollment
523
Phase
PHASE3
Primary Completion Date
2023-09-06
Status
COMPLETED
relationships
The graph out of here
drug
ALKS 3831
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophreniform Disorder
indication
Bipolar I Disorder
indication
Psychotic Disorders
indication
investigator
Alkermes Medical Director, MD
person